Qianliening capsule inhibits benign prostatic hyperplasia angiogenesis via the HIF‑1α signaling pathway

Lin,Jiumao; Zhou,Jianheng; Xu,Wei; Hong,Zhenfeng; Peng,Jun

doi:10.3892/etm.2014.1723

Qianliening capsule inhibits benign prostatic hyperplasia angiogenesis via the HIF‑1α signaling pathway

Authors:
- Jiumao Lin
- Jianheng Zhou
- Wei Xu
- Zhenfeng Hong
- Jun Peng
View Affiliations

Affiliations: Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China, Department of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China, Department of Pharmacology, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China, Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China
Published online on: May 19, 2014 https://doi.org/10.3892/etm.2014.1723
Pages: 118-124

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiogenesis plays an important role in the progression and development of benign prostatic hyperplasia (BPH), and has become a promising target for BPH treatment. The hypoxia‑inducible factor‑1α (HIF‑1α) signaling pathway promotes the process of angiogenesis, contributing to the growth and progression of a number of hyperplasia diseases, including BPH. Qianliening capsule (QC) is a traditional Chinese formula that has been used clinically in China to treat BPH for a number of years. Recently, QC was demonstrated to inhibit prostatic cell growth and induce apoptosis in vivo and in vitro via regulating the epidermal growth factor/signal transducer and activator of transcription 3 signaling pathway and mitochondrion‑dependent apoptosis pathway. However, the mechanisms underlying the anti‑BPH effect remain largely unknown. To further elucidate the mechanism of QC activity in BPH treatment, a rat BPH model established by injecting testosterone following castration was established and the effect of QC on prostatic tissue angiogenesis was evaluated, as well as the underlying molecular mechanisms. QC was shown to reduce the prostatic index in BPH rats, but without affecting the body weight, demonstrating that QC is effective in the treatment of BPH and without apparent toxicity. In addition, QC treatment significantly reduced the intraprostatic microvessel density, indicating antiangiogenesis activity in vivo. In addition, treatment with QC inhibited the expression of HIF‑1α in BPH rats, as well as the expression of vascular endothelial growth factor and basic fibroblast growth factor. Therefore, for the first time, the present study hypothesized that QC inhibits angiogenesis in prostatic tissue of BPH rats via the inhibition of the HIF‑1α signaling pathway, which may be one of the mechanisms in which QC treats BPH.

View Figures

View References

1	O’Malley KJ, Dhir R, Nelson JB, Bost J, Lin Y and Wang Z: The expression of androgen-responsive genes is up-regulated in the epithelia of benign prostatic hyperplasia. Prostate. 69:1716–1723. 2009.PubMed/NCBI
2	Paolone DR: Benign prostatic hyperplasia. Clin Geriatr Med. 26:223–239. 2010. View Article : Google Scholar
3	Roehrborn CG: Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 95:87–100. 2011. View Article : Google Scholar : PubMed/NCBI
4	Oh SJ: Unsolved issues in managing benign prostatic hyperplasia. Korean J Urol. 54:349–350. 2013. View Article : Google Scholar : PubMed/NCBI
5	Folkman J: Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology. 139:441–442. 1998. View Article : Google Scholar : PubMed/NCBI
6	Soulitzis N, Karyotis I, Delakas D and Spandidos DA: Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol. 29:305–314. 2006.PubMed/NCBI
7	Ren J, Huan Y, Wang H, et al: Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis. Clin Radiol. 63:153–159. 2008. View Article : Google Scholar : PubMed/NCBI
8	Lucia MS and Lambert JR: Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep. 9:272–278. 2008. View Article : Google Scholar : PubMed/NCBI
9	Bostanci Y, Kazzazi A, Momtahen S, Laze J and Djavan B: Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol. 23:5–10. 2013. View Article : Google Scholar : PubMed/NCBI
10	Lin JM, Zhao JY, Zhuang QC, Hong ZF and Peng J: Xiongshao capsule promotes angiogenesis of HUVEC via enhancing cell proliferation and up-regulating the expression of bFGF and VEGF. Chin J Integr Med. 17:840–846. 2011. View Article : Google Scholar : PubMed/NCBI
11	Folkman J: Angiogenesis. Annu Rev Med. 57:1–18. 2006. View Article : Google Scholar
12	Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 333:1757–1763. 1995. View Article : Google Scholar : PubMed/NCBI
13	Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007. View Article : Google Scholar : PubMed/NCBI
14	Lin CM, Chiu JH, Wu IH, Wang BW, Pan CM and Chen YH: Ferulic acid augments angiogenesis via VEGF, PDGF and HIF-1 alpha. J Nutr Biochem. 21:627–33. 2010. View Article : Google Scholar : PubMed/NCBI
15	Shi YH, Bingle L, Gong LH, Wang YX, Corke KP and Fang WG: Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells. Pathology. 39:396–400. 2007. View Article : Google Scholar : PubMed/NCBI
16	Andrikopoulou E, Zhang X, Sebastian R, et al: Current insights into the role of HIF-1 in cutaneous wound healing. Curr Mol Med. 11:218–235. 2011. View Article : Google Scholar : PubMed/NCBI
17	Hong XY, Wang J and Li Z: AGR2 expression is regulated by HIF-1 and contributes to growth and angiogenesis of glioblastoma. Cell Biochem Biophys. 67:1487–1495. 2013. View Article : Google Scholar : PubMed/NCBI
18	Risau W: Mechanisms of angiogenesis. Nature. 386:671–674. 1997. View Article : Google Scholar : PubMed/NCBI
19	Lin J, Wei L, Xu W, Hong Z, Liu XX and Peng J: Effect of Hedyotis Diffusa Willd extract on tumor angiogenesis. Mol Med Rep. 4:1283–1288. 2011.PubMed/NCBI
20	Goto F, Goto K, Weindel K and Folkman J: Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest. 69:508–517. 1993.
21	Prior BM, Yang HT and Terjung RL: What makes vessels grow with exercise training? J Appl Physiol (1985). 97:1119–1128. 2004. View Article : Google Scholar : PubMed/NCBI
22	Roehrborn CG, Nuckolls JG, Wei JT and Steers W; BPH Registry and Patient Survey Steering Committee. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics. BJU Int. 100:813–819. 2007. View Article : Google Scholar
23	Black L, Naslund MJ, Gilbert TD Jr, Davis EA and Ollendorf DA: An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care. 12(4 Suppl): S99–S110. 2006.PubMed/NCBI
24	MacDonald R and Wilt TJ: Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology. 66:780–788. 2005. View Article : Google Scholar : PubMed/NCBI
25	Djavan B and Marberger M: A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 36:1–13. 1999. View Article : Google Scholar : PubMed/NCBI
26	Gormley GJ, Stoner E, Bruskewitz RC, et al: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 327:1185–1191. 1992. View Article : Google Scholar : PubMed/NCBI
27	Roehrborn CG, Boyle P, Nickel JC, et al; ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 60:434–441. 2002. View Article : Google Scholar : PubMed/NCBI
28	Boyle P, Robertson C, Lowe F and Roehrborn C: Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology. 55:533–539. 2000. View Article : Google Scholar : PubMed/NCBI
29	Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C and Lau J: Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev. CD0010432000.PubMed/NCBI
30	Wilt T, Ishani A, Mac Donald R, Rutks I and Stark G: Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. CD0010442002.PubMed/NCBI
31	Lin JM, Huang YP, Zhou Jh and Hong ZF: Therapeutic efficacy of Qianliening capsules in the treatment of benign prostatic hyperplasia. Yatai Chuantong Yiyao. 9:140–143. 2013.(In Chinese).
32	Zhou J, Lin J, Xu W, Zhong X, Zheng Y, Hong Z and Peng J: Qianliening capsule treats benign prostatic hyperplasia through regulating the expression of sex hormones, estrogen receptor and androgen receptor. Afr J Pharm and Pharmacol. 6:173–180. 2012. View Article : Google Scholar
33	Zhong X, Lin J, Zhou J, Xu W, Hong Z and Peng J: Qianliening capsule treats benign prostatic hyperplasia (BPH) by down-regulating the expression of PCNA, CyclinD1 and CDK4. Afr J Biotechnol. 11:7731–7737. 2012.
34	Zheng H, Xu W, Lin J, Peng J and Hong ZF: Qianliening capsule treats benign prostatic hyperplasia via induction of prostatic cell apoptosis. Mol Med Rep. 7:848–854. 2013.PubMed/NCBI
35	Lin J, Zhou J, Xu W, Zhong X, Hong Z and Peng J: Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway. Exp Ther Med. 5:1293–1300. 2013.PubMed/NCBI
36	Hong ZF, Lin JM, Zhong XY, et al: Qianliening capsule inhibits human prostate cell growth via induction of mitochondrion-dependent cell apoptosis. Chin J Integr Med. 18:824–830. 2012. View Article : Google Scholar : PubMed/NCBI
37	Zheng HY, Xu W, Lin JM, Li H, Zhou JH and Hong ZF: Toxicological studies on qianliening capsule. Zhe Jiang Zhong Yi Yao Da Xue Xue Bao Bian Ji Bu. 35:63–65. 462011.(In Chinese).
38	Tang J and Yang J: Etiopathogenesis of benign prostatic hyperplasia. Indian J Urol. 25:312–317. 2009. View Article : Google Scholar
39	Bosch RJ: Pathogenesis of benign prostatic hyperplasia. Eur Urol. 20(Suppl 1): 27–30. 1991.
40	Huang YP, Du J, Hong ZF, Chen ZQ, Wu JF and Zhao JY: Effects of Kangquan Recipe on sex steroids and cell proliferation in rats with benign prostatic hyperplasia. Chin J Integr Med. 15:289–292. 2009. View Article : Google Scholar : PubMed/NCBI
41	Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 29(6 Suppl 16): 10–14. 2002. View Article : Google Scholar : PubMed/NCBI